GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice.
体外研究
GLP-1(32-36)amide (0.1-10 μM; 24 h) retains cell viability and decreases apoptosis against Streptozotocin (STZ; 1 μM) in INS‐1 cells.
Cell Viability Assay
Cell Line:
INS‐1 cells
Concentration:
0.1, 1, 10 μM
Incubation Time:
24 hours
Result:
Decreased cell viability only approximately 30% in 0.1 μM and approximately 20% in ≥1 μM while approximately 45% in saline-treated controls.
体内研究
GLP-1(32-36)amide (1 μmol/kg; i.p. once daily for 21 d) protects islet from damage, inhibits weight gain, and relieves symptoms of polydipsia in diabetic mice.
GLP-1(32-36)amide (1 μmol/kg; a single i.p.) slightly reduces the mean glucose lever at 30 min after the challenge of glucose in normal mice.
GLP-1(32-36)amide (50-70 nmol/kg/d; infusion for 12-16 weeks) prevents the development of diet-induced obesity and hepatic steatosis in high fat-fed mice.
Animal Model:
Male KM mice (6-8 weeks; 18-22 g) injected with STZ
Dosage:
1 μmol/kg
Administration:
I.p. once daily for 21 days
Result:
Significantly lowered the cumulative values of food and water intake.
Lowered fasting glucose.
Reduced the level of Hemoglobin A1c (HbA1c).
Improved glucose tolerance.
Suppressed body weight gain.
分子式
C25H50N10O5
分子量
570.73
CAS号
1417302-71-6
运输条件
Room temperature in continental US; may vary elsewhere.